Fused heterocyclic compounds and their use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9550764
APP PUB NO 20150232462A1
SERIAL NO

14421503

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof for use in the treatment of cancer:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL123 OLD BROMPTON ROAD LONDON SW7 3RP

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barbeau, Olivier Remi Sutton, GB 1 0
Cheeseman, Matthew David Sutton, GB 1 0
Faisal, Amir Sutton, GB 1 0
Jones, Keith Sutton, GB 53 552
Kalusa, Andrew Sutton, GB 1 0
Linardopoulos, Spyridon Sutton, GB 4 5

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 24, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00